Bukwang Pharm Co Ltd (003000)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bukwang Pharm Co Ltd (003000) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014380
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bukwang PharmCo Ltd (BUKWANG) is a pharmaceutical company which develops pharmaceutical products and new drugs. The company’s product portfolio includes levovir, legalon, dexid, thioctacid, lonasen, ixel, Orfil, azeptin, asima among others. Its pipeline products comprise MLR-1023, JM-010, JM-012 and SOL-804. BUKWANG offers its products in the therapeutic areas of Liver disease, Diabetes, Central Nervous System (CNS) disorders, Respiratory diseases, Prostate cancer, Parkinson’s disease and others. The company also offers services such as clinical development, regulatory development, and product development. Its products are used for treating hepatitis B-virus, diabetic neuropathy, liver damage, seasonal allergies and bronchial asthma. It operates through a research and development center located in Korea. BUKWANG is headquartered in Seoul, South Korea.

Bukwang Pharm Co Ltd (003000) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Bukwang Pharma Enters into Partnership with TVM Capital Life Science 10
Bukwang Pharma Enters Into Co-Development Agreement With LSK BioPartner And West Coast Clinical 11
Licensing Agreements 13
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 13
Melior Pharma Enters Into Licensing Agreement With Bukwang Pharma 14
Acquisition 15
Bukwang Pharma Acquires Contera Pharma 15
Bukwang Pharm Co Ltd – Key Competitors 16
Bukwang Pharm Co Ltd – Key Employees 17
Bukwang Pharm Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bukwang Pharm Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Bukwang Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bukwang Pharma Enters into Partnership with TVM Capital Life Science 10
Bukwang Pharma Enters Into Co-Development Agreement With LSK BioPartner And West Coast Clinical 11
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 13
Melior Pharma Enters Into Licensing Agreement With Bukwang Pharma 14
Bukwang Pharma Acquires Contera Pharma 15
Bukwang Pharm Co Ltd, Key Competitors 16
Bukwang Pharm Co Ltd, Key Employees 17
Bukwang Pharm Co Ltd, Other Locations 18
Bukwang Pharm Co Ltd, Subsidiaries 18

★海外企業調査レポート[Bukwang Pharm Co Ltd (003000)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vericel Corp (VCEL)-製薬・医療分野:企業M&A・提携分析
    Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell thera …
  • Wesfarmers Limited:企業の戦略・SWOT・財務情報
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ARK Diagnostics Inc:企業の製品パイプライン分析
    Summary ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lam …
  • GP Batteries International Ltd:企業の戦略的SWOT分析
    GP Batteries International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Transgene Biotek Ltd (526139):企業の財務・戦略的SWOT分析
    Summary Transgene Biotek Ltd (Transgene) is a biotechnology company that develops and commercializes bio-generic drugs and vaccines to treat autoimmune diseases and cancer. The company’s product portfolio includes TrabiDHA, a vegetarian source of DHA (Docosahexaenoic acid), used to manufacture healt …
  • Gardiner & Theobald LLP:企業の戦略的SWOT分析
    Gardiner & Theobald LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • IBEX Technologies Inc (IBT):企業の財務・戦略的SWOT分析
    Summary IBEX Technologies Inc (IBEX) is a manufacturer and marketer of high-purity proprietary enzymes and recombinant from flavobacterium heparinum. The company provides enzymes such as heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. Its assays allow for the stu …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DKSH Holding Ltd. (DKSH):企業の財務・戦略的SWOT分析
    DKSH Holding Ltd. (DKSH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • OncoMed Pharmaceuticals Inc (OMED):製薬・医療:M&Aディール及び事業提携情報
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …
  • Hoosier Energy Rural Electric Cooperative, Inc.:発電所・企業SWOT分析
    Hoosier Energy Rural Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, …
  • CGN New Energy Holdings Co Ltd (1811):企業の財務・戦略的SWOT分析
    CGN New Energy Holdings Co Ltd (1811) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Holland Board of Public Works:企業の戦略的SWOT分析
    Holland Board of Public Works - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • SYNNEX Corp (SNX):企業の財務・戦略的SWOT分析
    SYNNEX Corp (SNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vonovia SE:企業の戦略・SWOT・財務分析
    Vonovia SE - Strategy, SWOT and Corporate Finance Report Summary Vonovia SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Lianhe Chemical Technology Co., Ltd. (002250):企業の財務・戦略的SWOT分析
    Lianhe Chemical Technology Co., Ltd. (002250) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Petronas Dagangan Bhd (PETDAG):石油・ガス:M&Aディール及び事業提携情報
    Summary Petronas Dagangan Bhd (Petronas Dagangan), a subsidiary of Petroliam Nasional Berhad, is an oil and gas company that retails and markets downstream oil and gas products. The company operates through its business segments such as retail, commercial, liquefied petroleum gas and lubricants. It …
  • Optex Systems Holdings, Inc.:企業の戦略・SWOT・財務情報
    Optex Systems Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Optex Systems Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • OncoMed Pharmaceuticals Inc (OMED):企業の財務・戦略的SWOT分析
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆